FDA OKs Abemaciclib for ER+, HER2- Breast Cancer [News in Brief]
The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy. This is the third CDK4/6 inhibitor to get the agency's go-ahead in 2.5 years. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Chiou, S.-H., Risca, V. I., Wang, G. X., Yang, D., Grüner, B. M., Kathiria, A. S., Ma, R. K., Vaka, D., Chu, P., Kozak, M., Castellini, L., Graves, E. E., Kim, G. E., Mourrain, P., Koong, A. C., Giaccia, A. J., Winslow, M. M. Tags: Research Articles Source Type: research
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Haricharan, S., Punturi, N., Singh, P., Holloway, K. R., Anurag, M., Schmelz, J., Schmidt, C., Lei, J. T., Suman, V., Hunt, K., Olson, J. A., Hoog, J., Li, S., Huang, S., Edwards, D. P., Kavuri, S. M., Bainbridge, M. N., Ma, C. X., Ellis, M. J. Tags: Research Articles Source Type: research
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Ruella, M., Klichinsky, M., Kenderian, S. S., Shestova, O., Ziober, A., Kraft, D. O., Feldman, M., Wasik, M. A., June, C. H., Gill, S. Tags: Research Articles Source Type: research
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RAR{alpha} Dependency Targetable by SY-1425, a Potent and Selective RAR{alpha} Agonist [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: McKeown, M. R., Corces, M. R., Eaton, M. L., Fiore, C., Lee, E., Lopez, J. T., Chen, M. W., Smith, D., Chan, S. M., Koenig, J. L., Austgen, K., Guenther, M. G., Orlando, D. A., Loven, J., Fritz, C. C., Majeti, R. Tags: Research Articles Source Type: research
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., Choo, S. P., Myint, S. S., Thanan, R., Nagarajan, S., Lim, W. K., Ng, C. C. Y., Boot, A., Liu, M., Ong, C. K., Rajase Tags: Research Articles Source Type: research
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition [Research Articles]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Gil Del Alcazar, C. R., Huh, S. J., Ekram, M. B., Trinh, A., Liu, L. L., Beca, F., Zi, X., Kwak, M., Bergholtz, H., Su, Y., Ding, L., Russnes, H. G., Richardson, A. L., Babski, K., Min Hui Kim, E., McDonnell, C. H., Wagner, J., Rowberry, R., Freeman, G. J Tags: Research Articles Source Type: research
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence [Research Brief]
This article is highlighted in the In This Issue feature, p. 1047 (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Reuben, A., Gittelman, R., Gao, J., Zhang, J., Yusko, E. C., Wu, C.-J., Emerson, R., Zhang, J., Tipton, C., Li, J., Quek, K., Gopalakrishnan, V., Chen, R., Vence, L. M., Cascone, T., Vignali, M., Fujimoto, J., Rodriguez-Canales, J., Parra, E. R., Little, Tags: Research Brief Source Type: research
How Ribosomes Translate Cancer [Review]
A wealth of novel findings, including congenital ribosomal mutations in ribosomopathies and somatic ribosomal mutations in various cancers, have significantly increased our understanding of the relevance of ribosomes in oncogenesis. Here, we explore the growing list of mechanisms by which the ribosome is involved in carcinogenesis—from the hijacking of ribosomes by oncogenic factors and dysregulated translational control, to the effects of mutations in ribosomal components on cellular metabolism. Of clinical importance, the recent success of RNA polymerase inhibitors highlights the dependence on "onco-ribosomes" as a...
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Sulima, S. O., Hofman, I. J. F., De Keersmaecker, K., Dinman, J. D. Tags: Review Source Type: research
Soils and Seeds That Initiate Pancreatic Cancer Metastasis [In the Spotlight]
Summary: Pathways that stimulate metastasis of pancreatic cancer cells are critical for understanding tumor evolution and can serve as potential therapeutic targets. The microenvironment produces a host of metabolic perturbations and tropic factors that may play a formative role in this process. Cancer Discov; 7(10); 1067–8. ©2017 AACR.
See related article by Chiou et al., p. 1184. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Vakoc, C. R., Tuveson, D. A. Tags: In the Spotlight Source Type: research
Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite [In the Spotlight]
In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sensitive to SY-1425, a highly potent RARA agonist able to induce myeloid differentiation in these high-expressing RARA AML subtypes. Cancer Discov; 7(10); 1065–6. ©2017 AACR.
See related article by McKeown et al., p. 1136. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Wang, E., Aifantis, I. Tags: In the Spotlight Source Type: research
More T Cells versus Better T Cells in Patients with Breast Cancer [In the Spotlight]
Summary: Characterization of intratumoral leukocyte populations may help in estimating patients' prognosis and predictions. A new study shows remarkable differences between the in situ and invasive breast cancer stages and highlights that cell number analyses should be complemented with characterization of T-cell functions, increasing the likelihood that immune competent antitumor T cells and further biomarkers are identified for guiding therapy choices. Cancer Discov; 7(10); 1062–4. ©2017 AACR.
See related article by Gil Del Alcazar et al., p. 1098. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Authors: Speiser, D. E., Verdeil, G. Tags: In the Spotlight Source Type: research
CMTM6 Regulates PD-L1 Expression and Antitumor Immunity [Immunotherapy]
CMTM6 binds to PD-L1 on the plasma membrane to promote its stability and inhibitory activity. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Osimertinib May Be an Effective First-Line Therapy in EGFR-Mutant NSCLC [Clinical Trials]
Osimertinib achieved objective responses in 77% of patients with treatment-naïve NSCLC. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Vitamin C Restores TET2 Activity in TET2-Deficient Leukemia [Leukemia]
TET2 restoration promotes DNA demethylation and differentiation to suppress leukemic progression. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
